Product Description
MiNK-215 are fibrogen active protein (FAP) targeting T-cells being developed by Agenus and MINK Therapeutics. (Sourced from: https://investor.agenusbio.com/static-files/3fd0754b-cb11-45bc-96db-e3c1d7fd1b2c)
Mechanisms of Action: Cell Therapy, FAP
Novel Mechanism: Yes
Modality: Cell Therapy
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Agenus
Company Location: Eastern America
Company CEO: Garo H. Armen
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
- Clinical Outcomes Reported - Agenus presented P0 Oncology Solid Tumor Unspecified results on 2025-11-20 for MiNK-215
Highest Development Phases
Phase 0: Non-Small-Cell Lung Cancer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|